Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Oncology '96].

× No keyword cloud information.

189 in total

1. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

Authors: J Baselga; D Tripathy; J Mendelsohn; S Baughman; C C Benz; L Dantis; N T Sklarin; A D Seidman; C A Hudis; J Moore; P P Rosen; T Twaddell; I C Henderson; L Norton
Journal: J Clin Oncol Date: 1996-03 Impact factor: 44.544

2. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity.

Authors: R J Motzer; M Mazumdar; G J Bosl; D F Bajorin; A Amsterdam; V Vlamis
Journal: J Clin Oncol Date: 1996-04 Impact factor: 44.544

3. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery.

Authors: H Wada; S Hitomi; T Teramatsu
Journal: J Clin Oncol Date: 1996-04 Impact factor: 44.544

4. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.

Authors: W P McGuire; J A Blessing; D Moore; S S Lentz; G Photopulos
Journal: J Clin Oncol Date: 1996-03 Impact factor: 44.544

5. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.

Authors: J T Thigpen; J A Blessing; P J DiSaia; E Yordan; L F Carson; C Evers
Journal: J Clin Oncol Date: 1994-07 Impact factor: 44.544

6. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study.

Authors: W S Dalton; J J Crowley; S S Salmon; T M Grogan; L R Laufman; G R Weiss; J D Bonnet
Journal: Cancer Date: 1995-02-01 Impact factor: 6.860

7. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.

Authors: D L Fraker; H R Alexander; M Andrich; S A Rosenberg
Journal: J Clin Oncol Date: 1996-02 Impact factor: 44.544

8. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.

Authors: W H Wilson; S E Bates; A Fojo; G Bryant; Z Zhan; J Regis; R E Wittes; E S Jaffe; S M Steinberg; J Herdt
Journal: J Clin Oncol Date: 1995-08 Impact factor: 44.544

9. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group.

Authors: E Bayerdörffer; A Neubauer; B Rudolph; C Thiede; N Lehn; S Eidt; M Stolte
Journal: Lancet Date: 1995-06-24 Impact factor: 79.321

10. Genetic diagnosis of lymph-node metastasis in colorectal cancer.

Authors: N Hayashi; I Ito; A Yanagisawa; Y Kato; S Nakamori; S Imaoka; H Watanabe; M Ogawa; Y Nakamura
Journal: Lancet Date: 1995-05-20 Impact factor: 79.321